Talk:Umbralisib
| This is the talk page for discussing improvements to the Umbralisib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Umbralisib.
|
Also in a trial of a triplet regimen
[1] with ublituximab and ibrutinib, in various subtypes of non-Hodgkin lymphoma (NHL). - Need RS and NCT# - Rod57 (talk) 19:02, 20 December 2017 (UTC)
Disagree with adding the barrientos article
The commentary by Jacqueline Barrientos is biased in regard to only focusing on Idelalisib as being an approved Pi3k medication, although last year another Pi3k inhibitor, copanlisib, has been approved by US FDA for treatment of Follicular lymphoma (is an NHL type) that relapsed after two prior systemic therapies. Please note that Ms Barrientos is heavily Coi'd (see her reporting in the respective commentary), amongst it Gilead, the producer of Idelalisib. Given her neglecting of another approved pi3k inhibitor in NHL, as well as her financial COI, I think this article should not be referred here for reasons of neutrality!
Instead, if you think a citation is needed, I propose to cite the actual Umbralisib article (and not the commentary).
(And for transparency, please see my own coi on my user page, as Copanlisib is produced by Bayer). Wowbagger2 (talk) 19:42, 1 March 2018 (UTC)